Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UM171 Expanded Cord Blood for Allogeneic HSCT
NCT02668315Phase 2Completed
- Sponsor
- Hôpital Maisonneuve-Rosemont
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of dorocubicel in hematologic malignancy, sponsored by Hôpital Maisonneuve-Rosemont. Started Dec 2015; status: completed.
02
Drugs
dorocubicel
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02668315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668315.